Novo Nordisk A/S (BKK:NOVOB80)

Market Cap	6.49T -36.1%
Revenue (ttm)	1.65T +8.1%
Net Income	614.02B +16.6%
EPS	138.01 +16.8%
Shares Out	n/a
PE Ratio	10.57
Forward PE	14.23
Dividend	0.04 (2.83%)
Ex-Dividend Date	Mar 27, 2026

Volume	852,759
Open	1.490
Previous Close	1.490
Day's Range	1.470 - 1.500
52-Week Range	1.120 - 2.700
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 67,900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: NOVOB80

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK